PENSACOLA, FL, USA, Nov 10, 2025/ Farcast, a pioneer and leader in human tumor microdynamics research, today announced the presentation of new data at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data highlight significant advances in understanding immune responsiveness across multiple tumor types, demonstrating the power of the company’s TruTumor™ treatment response and resistance prediction system.

One study focused on colorectal cancer (CRC), a disease known for highly variable and often limited response to immune checkpoint inhibitors. The study confirmed the strongly immunosuppressive nature of CRC, driven in part by deep and potentially irreversible exhaustion of CD8+ T cells. The data presented validated the platform’s ability not only to stratify responders from non-responders but also to identify rational combination therapies that could enhance treatment sensitivity.

In the second study presented at SITC, Farcast partnered with SurgeCare to evaluate immune response dynamics in a cohort of 23 head and neck squamous cell carcinoma (HNSCC) tumors analyzed in the Farcast TruTumor™ system with Nivolumab. Leveraging SurgeCare’s Stabl algorithm, the teams conducted an AI-driven stratification of responders and non-responders using an unlabeled dataset comprising 849 features from cytokine profiling, flow cytometry, NanoString assays, and histopathology. The strengths of the two proprietary technologies honed in on 25 key features that comprehensively explained response phenotypes observed in the study cohort. Based on these features, the samples were stratified into three biologically meaningful clusters each associated with distinct immune ecosystem characteristics that accounted for differential treatment sensitivity. Furthermore, an additional response-associated feature originating from the myeloid compartment of the tumor microenvironment (TME) added strength to the predictive model and reinforced the power of functional biosignatures seen in the study.

“These results demonstrate the value of Farcast’s system which starts by interrogating the functional responses to treatment in the intact tumor microenvironment, unlike most others that focus on cellular or even insilico profiles without the contexture of the native microenvironment. We have also been progressing our system to integrate the spatial layer and subsequently the peripheral, systemic layer, and I could not be more excited to see what clinically useful secrets we will be able to unlock using this approach. The collaboration with SurgeCare further proves the benefit of applying advanced AI methods to increase the precision and robustness of biosignature discovery, even in studies with fewer number of samples” said Mohit Malhotra, CEO of Farcast.